...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical lung cancer >Phase II Trial of Sequential Chemotherapy Followed by Chemoradiation, Surgery, and Postoperative Chemotherapy for the Treatment of Stage IIIA/IIIB Non-Small-Cell Lung Cancer.
【24h】

Phase II Trial of Sequential Chemotherapy Followed by Chemoradiation, Surgery, and Postoperative Chemotherapy for the Treatment of Stage IIIA/IIIB Non-Small-Cell Lung Cancer.

机译：序贯化学疗法的II期试验，然后进行化学放疗，手术和术后化学疗法治疗IIIA / IIIB期非小细胞肺癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The optimal treatment of locally advanced non-small-cell lung cancer remains a challenge. Although the benefit of combined chemoradiation has been established, the optimal chemotherapy regimen, timing of full-dose chemotherapy, and how best to combine chemotherapy with radiation to maximize systemic and radiosensitizing effects remain unclear. PATIENTS AND METHODS: Twenty-nine patients with pathologically confirmed stage IIIA/IIIB non-small-cell lung cancer were included in a phase II trial of sequential carboplatin/paclitaxel followed by chemoradiation, surgery, and postoperative gemcitabine. Twenty-five patients (86%) completed the concurrent chemotherapy and radiation therapy phase and were eligible for surgery. At restaging, 7 patients (21%) showed disease progression. Seventeen patients (59%) went on to surgery. Few were able to tolerate full postoperative chemotherapy. RESULTS: The 1-year overall survival rate was 61%, with a 2-year survival rate of 56%. Median overall survival was 25.2 months. Seven of the patients are alive and without recurrence at the time of this writing. Our median follow-up time was 22.2 months. Reversible grade 3/4 toxicities were fairly common, experienced in 45% of patients. CONCLUSION: Our results with this combined modality approach are comparable with those of previous, similar studies. Postoperative chemotherapy after initial combined modality therapy is often not feasible, reinforcing the value of initial systemic therapy. Long-term results are still suboptimal and await studies adding targeted therapies to our usual chemotherapy/radiation approaches.
机译：背景：局部晚期非小细胞肺癌的最佳治疗仍然是一个挑战。尽管已经确立了联合化学放疗的益处，但是尚不清楚最佳的化学疗法方案，全剂量化学疗法的时机以及如何最佳地将化学疗法与放射疗法结合以最大程度地发挥全身和放射增敏作用。患者和方法：29例经病理证实的IIIA / IIIB期非小细胞肺癌的患者纳入了依次用卡铂/紫杉醇进行的II期临床试验，随后进行化学放射，手术和术后吉西他滨治疗。 25名患者（86％）完成了同时进行的化学疗法和放射疗法阶段，并且有资格接受手术。再分期时，有7名患者（21％）表现出疾病进展。 17名患者（59％）接受了手术。几乎没有人能够耐受完整的术后化疗。结果：1年总生存率为61％，2年生存率为56％。中位总生存期为25.2个月。在撰写本文时，有七名患者还活着并且没有复发。我们的中位随访时间为22.2个月。可逆的3/4级毒性相当普遍，在45％的患者中经历过。结论：我们采用这种联合方法的结果与以前类似研究的结果相当。初始联合模态疗法后的术后化疗通常不可行，从而增强了初始全身疗法的价值。长期结果仍不是最佳选择，有待研究将靶向疗法添加到我们通常的化学疗法/放射疗法中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号